Das trockene Auge: Ein Update über Epidemiologie, Diagnose

Weitere Magazine

Empfehlungen

Info

und sichere, pharmakologisch basierte Therapie der Keratokonjunktivitis sicca. Fazit für die Praxis Für die Therapie des trockenen Auges werden die Tränensubstitution und die Verbesserung der Tränenfilmqualität sowie der Effizienz der Tränennutzung weiterhin eine wichtige Rolle spielen. Es haben sich jedoch gerade in den letzten Jahren durch eine sehr zeit- und kostenintensive Grundlagenforschung die Kenntnisse der Physiologie und Pathophysiologie der Augenoberfläche und des Tränenfilms exponentiell vermehrt. Nur auf der Basis solcher Erkenntnisse können Konzepte wachsen und schließlich zu nutzbarem Wissen werden. Die Zeit der „ersten Ernte“ scheint jetzt in greifbare Nähe gerückt zu sein. Gelingt es nun, innerhalb weniger Jahre, in neue Dimensionen der Therapie des trockenen Auges vorzustoßen, die in den letzten 20 Jahren kaum erreichbar schienen? Weltweit warten über 100 Millionen betroffene Menschen auf eine Antwort. Korrespondierender Autor Dr. F. Schirra Literatur Universitäts-Augenklinik, Kirrberger Straße 1, 66421 Homburg/Saar E-Mail: frank.schirra@unikliniksaarland.de 1. Aragona P, Papa V, Micali A, Santocono M, Milazzo G (2002) Long term treatment with sodium hyaluronatecontaining artificial tears reduces ocular surface damage in patients with dry eye. Br J Ophthalmol 86:181–184 2. Bacman S, Berra A, Sterin-Borda L, Borda E (2001) Muscarinic acetylcholine receptor antibodies as a new marker of dry eye Sjogren syndrome. Invest Ophthalmol Vis Sci 42:321–327 3. Balaram M, Schaumberg DA, Dana MR (2001) Efficacy and tolerability outcomes after punctal occlusion with silicone plugs in dry eye syndrome. Am J Ophthalmol 131:30–36 4. Blades KJ, Patel S, Aidoo KE (2001) Oral antioxidant therapy for marginal dry eye. Eur J Clin Nutr 55:589–597 5. Brignole F, Pisella PJ, De Saint Jean M, Goldschild M, Goguel A, Baudouin C (2001) Flow cytometric analysis of inflammatory markers in KCS: 6-month treatment with topical cyclosporin A. Invest Ophthalmol Vis Sci 42:90–95 6. Brignole F, Pisella PJ, Goldschild M, De Saint Jean M, Goguel A, Baudouin C (2000) Flow cytometric analysis of inflammatory markers in conjunctival epithelial cells of patients with dry eyes. Invest Ophthalmol Vis Sci 41:1356–1363 7. Bron AJ, Evans VE, Smith JA (2003) Grading of corneal and conjunctival staining in the context of other dry eye tests. Cornea 22:640–650 8. Chia EM, Mitchell P, Rochtchina E, Lee AJ, Maroun R, Wang JJ (2003) Prevalence and associations of dry eye syndrome in an older population: the Blue Mountains Eye Study. Clin Experiment Ophthalmol 31:229–232 9. Craig JP, Singh I,Tomlinson A, Morgan PB, Efron N (2000) The role of tear physiology in ocular surface temperature. Eye 14:635–641 10. Cross WD, Lay LF,Walt JG, Kozma CM (2002) Clinical and economic implications of topical cyclosporin A for the treatment of dry eye. Manag Care Interface 15:44–49 11. De Paiva CS, Harris LD, Pflugfelder SC (2003) Keratoconus-like topographic changes in keratoconjunctivitis sicca. Cornea 22:22–24 12. Debbasch C, De La Salle SB, Brignole F, Rat P,Warnet JM, Baudouin C (2002) Cytoprotective effects of hyaluronic acid and Carbomer 934P in ocular surface epithelial cells. Invest Ophthalmol Vis Sci 43:3409–3415 13. Dinslage S, Stoffel W, Diestelhorst M, Krieglstein GK (2002) Tolerability and safety of two new preservativefree tear film substitutes. Cornea 21:352–355 14. Doughty MJ, Blades KA, Ibrahim N (2002) Assessment of the number of eye symptoms and the impact of some confounding variables for office staff in non-airconditioned buildings. Ophthalmic Physiol Opt 22:143–155 15. Dursun D, Ertan A, Bilezikci B, Akova YA, Pelit A (2003) Ocular surface changes in keratoconjunctivitis sicca with silicone punctum plug occlusion. Curr Eye Res 26:263–269 16. Farrell J, Patel S, Grierson DG, Sturrock RD (2003) A clinical procedure to predict the value of temporary occlusion therapy in keratoconjunctivitis sicca. Ophthalmic Physiol Opt 23:1–8 17. Fujihara T, Murakami T, Fujita H, Nakamura M, Nakata K (2001) Improvement of corneal barrier function by the P2Y(2) agonist INS365 in a rat dry eye model. Invest Ophthalmol Vis Sci 42:96–100 18. Fujihara T, Murakami T, Nagano T, Nakamura M, Nakata K (2002) INS365 suppresses loss of corneal epithelial integrity by secretion of mucin-like glycoprotein in a rabbit short-term dry eye model. J Ocul Pharmacol Ther 18:363–370 19. Gamache DA, McDonough TJ, Roberts L, Brady MT,Yanni JM (2003) The mucin secretagogue 15(S)-HETE protects the cornea and improves tear film integrity in a rabbit model of lacrimal gland inflammation induced dry eye. ARVO 2003 abstract #2498 20. Gamache DA,Wei ZY,Weimer LK, Miller ST, Spellman JM, Yanni JM (2002) Corneal protection by the ocular mucin secretagogue 15(S)-HETE in a rabbit model of desiccation-induced corneal defect. J Ocul Pharmacol Ther 18:349–361 21. Gamache DA,Wei ZY,Weimer LK, Spellman JM,Yanni JM (2002) Preservation of corneal integrity by the mucin secretagogue 15(S)-HETE in a rabbit model of desiccation-induced dry eye. Adv Exp Med Biol 506:335–340 22. Gao J, Schwalb TA, Addeo JV, Ghosn CR, Stern ME (1998) The role of apoptosis in the pathogenesis of canine keratoconjunctivitis sicca: the effect of topical Cyclosporin A therapy. Cornea 17:654–663 23. Geerling G, Hartwig D (2002) Autologous serum-eyedrops for ocular surface disorders. A literature review and recommendations for their application. Ophthalmologe 99:949–959 24. Geerling G, Honnicke K, Schroder C, Framme C, Sieg P, Lauer I, Pagel H, Kirschstein M, Seyfarth M, Marx AM, Laqua H (1999) Quality of salivary tears following autologous submandibular gland transplantation for severe dry eye. Graefes Arch Clin Exp Ophthalmol 237:546–553 25. Goto E, Monden Y,Takano Y, Mori A, Shimmura S, Shimazaki J,Tsubota K (2002) Treatment of non-inflamed obstructive meibomian gland dysfunction by an infrared warm compression device. Br J Ophthalmol 86:1403–1407 26. Goto E, Shimazaki J, Monden Y,Takano Y,Yagi Y, Shimmura S,Tsubota K (2002) Low-concentration homogenized castor oil eye drops for noninflamed obstructive meibomian gland dysfunction. Ophthalmology 109:2030–2035 27. Goto E,Tseng SC (2003) Differentiation of lipid tear deficiency dry eye by kinetic analysis of tear interference images. Arch Ophthalmol 121:173–180 28. Goto E,Tseng SC (2003) Kinetic analysis of tear interference images in aqueous tear deficiency dry eye before and after punctal occlusion. Invest Ophthalmol Vis Sci 44:1897–1905 29. Goto E,Yagi Y, Kaido M, Matsumoto Y, Konomi K,Tsubota K (2003) Improved functional visual acuity after punctal occlusion in dry eye patients. Am J Ophthalmol 135:704–705 30. Goto T, Zheng X, Klyce SD, Kataoka H, Uno T, Karon M, Tatematsu Y, Bessyo T,Tsubota K, Ohashi Y (2003) A new method for tear film stability analysis using videokeratography. Am J Ophthalmol 135:607–612 31. Grus FH, Augustin AJ (1999) Analysis of tear protein patterns by a neural network as a diagnostical tool for the detection of dry eyes. Electrophoresis 20:875–880 32. Grus FH, Sabuncuo P, Augustin AJ (2001) Analysis of tear protein patterns of dry-eye patients using fluorescent staining dyes and two-dimensional quantification algorithms. Electrophoresis 22:1845–1850 33. Gunduz K, Ozdemir O (1994) Topical cyclosporin treatment of keratoconjunctivitis sicca in secondary Sjogren’s syndrome. Acta Ophthalmol 72:438–442 34. Gupta SK, Gupta V, Joshi S,Tandon R (2002) Subclinically dry eyes in urban Delhi: an impact of air pollution? Ophthalmologica 216:368–371 35. Herber S, Grus FH, Sabuncuo P, Augustin AJ (2001) Twodimensional analysis of tear protein patterns of diabetic patients. Electrophoresis 22:1838–1844 36. Isreb MA, Greiner JV, Korb DR, Glonek T, Mody SS, Finnemore VM, Reddy CV (2003) Correlation of lipid layer thickness measurements with fluorescein tear film break-up time and Schirmer’s test. Eye 17:79–83 37. Jamaliah R, Fathilah J (2002) Prevalence of dry eye in University Malaya Medical Centre. Med J Malaysia 57:390–397 38. Jones DT, Monroy D, Ji Z, Pflugfelder SC (1998) Alterations of ocular surface gene expression in Sjogren’s syndrome. Adv Exp Med Biol 438:533–536 39. Kellerman DJ, Sall KN, Bokosky JE, Mills-Wilson MC, Whitsell RS, Kaufman BD,Yerxa BR (2003) Diquafosol tetrasodium (INS365) ophthalmic solution is not absorbed systemically in patients with dry eye. ARVO 2003 abstract #3740 40. King-Smith PE, Fink BA, Fogt N (1999) Three interferometric methods for measuring the thickness of layers of the tear film. Optom Vis Sci 76:19–32 41. Koh S,Watanabe H, Hosohata J, Hori Y, Hibino S, Nishida K, Maeda N,Tano Y (2003) Diagnosing dry eye using a blue-free barrier filter. Am J Ophthalmol 136:513–519 42. Kunert KS,Tisdale AS, Gipson IK (2002) Goblet cell numbers and epithelial proliferation in the conjunctiva of patients with dry eye syndrome treated with cyclosporine. Arch Ophthalmol 120:330–337 43. Kunert KS,Tisdale AS, Stern ME, Smith JA, Gipson IK (2000) Analysis of topical cyclosporine treatment of patients with dry eye syndrome: effect on conjunctival lymphocytes. Arch Ophthalmol 118:1489–1496 44. Lee AJ, Lee J, Saw SM, Gazzard G, Koh D,Widjaja D,Tan DT (2002) Prevalence and risk factors associated with dry eye symptoms: a population based study in Indonesia. Br J Ophthalmol 86:1347–1351 Der Ophthalmologe 1 · 2004 | 17
45. Lemp MA (2000) Evaluation and differential diagnosis of keratoconjunctivitis sicca. J Rheumatol Suppl 61:11–14 46. Lin PY,Tsai SY, Cheng CY, Liu JH, Chou P, Hsu WM (2003) Prevalence of dry eye among an elderly chinese population in Taiwan: the Shihpai eye study. Ophthalmology 110:1096–1101 47. Liu D, Sadhan Y (2002) Surgical punctal occlusion: a prospective study. Br J Ophthalmol 86:1031–1034 48. Liu Z, Pflugfelder SC (1999) Corneal surface regularity and the effect of artificial tears in aqueous tear deficiency. Ophthalmology 106:939–943 49. Lopez Garcia JS, Garcia Lozano I, Martinez Garchitorena J (2003) Measure of the fatty layer thickness of precorneal tear film by interference colours in different types of dry eye. Arch Soc Esp Oftalmol 78:257–264 50. McDonald CC, Kaye SB, Figueiredo FC, Macintosh G, Lockett C (2002) A randomised, crossover, multicentre study to compare the performance of 0.1% (w/v) sodium hyaluronate with 1.4% (w/v) polyvinyl alcohol in the alleviation of symptoms associated with dry eye syndrome. Eye 16:601–607 51. Milazzo G, Papa V, Pasquale A, Russo S, Russo P, Di Bella A (2002) Efficacy of sodium hyaluronate eye drops of different osmolarities in the symptomatic treatment of dry eye patients. Adv Exp Med Biol 506:1233–1235 52. Moss SE, Klein R, Klein BE (2000) Prevalence of and risk factors for dry eye syndrome. Arch Ophthalmol 118:1264–1268 53. Mundasad MV, Novack GD, Allgood VE, Evans RM, Gorden JC,Yerxa BR (2001) Ocular safety of INS365 ophthalmic solution: a P2Y(2) agonist in healthy subjects. J Ocul Pharmacol Ther 17:173–179 54. Murube J, Murube E, ChenZhuo L, Rivas L (2003) Subcutaneous abdominal artificial tears pump-reservoir for severe dry eye. Orbit 22:29–40 55. Nemeth J, Erdelyi B, Csakany B, Gaspar P, Soumelidis A, Kahlesz F, Lang Z (2002) High-speed videotopographic measurement of tear film build-up time. Invest Ophthalmol Vis Sci 43:1783–1790 56. Nepp J, Schauersberger J, Schild G, Jandrasits K, Haslinger-Akramian J, Derbolav A,Wedrich A (2001) The clinical use of viscoelastic artificial tears and sodium chloride in dry-eye syndrome. Biomaterials 22:3305–3310 57. Ogawa Y, Okamoto S, Mori T,Yamada M, Mashima Y, Watanabe R, Kuwana M,Tsubota K, Ikeda Y, Oguchi Y (2003) Autologous serum eye drops for the treatment of severe dry eye in patients with chronic graft-versushost disease. Bone Marrow Transplant 31:579–583 58. Olson MC, Korb DR, Greiner JV (2003) Increase in tear film lipid layer thickness following treatment with warm compresses in patients with meibomian gland dysfunction. Eye Contact Lens 29:96–99 59. Papa V, Aragona P, Russo S, Di Bella A, Russo P, Milazzo G (2001) Comparison of hypotonic and isotonic solutions containing sodium hyaluronate on the symptomatic treatment of dry eye patients. Ophthalmologica 215:124–127 60. Sade de Paiva C, Lindsey JL, Pflugfelder SC (2003) Assessing the severity of keratitis sicca with videokeratoscopic indices. Ophthalmology 110:1102–1109 61. Sall K, Stevenson OD, Mundorf TK, Reis BL (2000) Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology 107:631–639 62. Schaumberg DA, Buring JE, Sullivan DA, Dana MR (2001) Hormone replacement therapy and dry eye syndrome. JAMA 286:2114–2119 63. Schein OD, Hochberg MC, Munoz B,Tielsch JM, Bandeen-Roche K, Provost T, Anhalt GJ,West S (1999) Dry eye and dry mouth in the elderly: a populationbased assessment. Arch Intern Med 159:1359–1363 | Der Ophthalmologe 1 · 2004 18 64. Schiffman RM,Walt JG, Jacobsen G, Doyle JJ, Lebovics G, Sumner W (2003) Utility assessment among patients with dry eye disease. Ophthalmology 110:1412–1419 65. Shimmura S, Shimazaki J,Tsubota K (1999) Results of a population-based questionnaire on the symptoms and lifestyles associated with dry eye. Cornea 18:408–411 66. Shimmura S, Ueno R, Matsumoto Y, Goto E, Higuchi A, Shimazaki J,Tsubota K (2003) Albumin as a tear supplement in the treatment of severe dry eye. Br J Ophthalmol 87:1279–1283 67. Singh G, Bhinder HS (2003) Closed chamber thermometry and humidity measurements in normal and dry eye patients: a pilot study. Eur J Ophthalmol 13:343-350 68. Small DS, Acheampong A, Reis B, Stern K, Stewart W, Berdy G, Epstein R, Foerster R, Forstot L,Tang-Liu DD (2002) Blood concentrations of cyclosporin a during long-term treatment with cyclosporin a ophthalmic emulsions in patients with moderate to severe dry eye disease. J Ocul Pharmacol Ther 18:411–418 69. Stern ME, Beuerman RW, Fox RI, Gao J, Mircheff AK, Pflugfelder SC (1998) The pathology of dry eye: the interaction between the ocular surface and lacrimal glands. Cornea 17:584–589 70. Stevenson D,Tauber J, Reis BL (2000) Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial.The Cyclosporin A Phase 2 Study Group. Ophthalmology 107:967–974 71. Sullivan DA,Yamagami H, Liu M, Steagall RJ, Schirra F, Suzuki T, Krenzer KL, Cermak JM, Sullivan RM, Richards SM, Schaumberg DA, Dana MR, Sullivan BD (2002) Sex steroids, the meibomian gland and evaporative dry eye. Adv Exp Med Biol 506:389–399 72. Sullivan RM, Cermak JM, Papas AS, Dana MR, Sullivan DA (2002) Economic and quality of life impact of dry eye symptoms in women with Sjogren’s syndrome. Adv Exp Med Biol 506:1183–1188 73. Tai MC, Cosar CB, Cohen EJ, Rapuano CJ, Laibson PR (2002) The clinical efficacy of silicone punctal plug therapy. Cornea 21:135–139 74. Takamura E, Shinozaki K, Hata H,Yukari J, Hori S (2002) Efficacy of autologous serum treatment in patients with severe dry eye. Adv Exp Med Biol 506:1247–1250 75. Tananuvat N, Daniell M, Sullivan LJ,Yi Q, McKelvie P, McCarty DJ,Taylor HR (2001) Controlled study of the use of autologous serum in dry eye patients. Cornea 20:802–806 76. Tauber J, Davitt WF, Bokosky JE, Nichols KK, Mills-Wilson MC, Schaberg AE,Yerxa BR, LaVange LM, Kenny SJ, Kellerman DJ (2003) Double masked, placebo-controlled safety and efficacy trial of diquafosol tetrasodium (INS365) ophthalmic solution for the treatment of dry eye. ARVO 2003 abstract #3738 77. Tsubota K, Goto E, Fujita H, Ono M, Inoue H, Saito I, Shimmura S (1999) Treatment of dry eye by autologous serum application in Sjogren’s syndrome. Br J Ophthalmol 83:390–395 78. Turner K, Pflugfelder SC, Ji Z, Feuer WJ, Stern M, Reis BL (2000) Interleukin-6 levels in the conjunctival epithelium of patients with dry eye disease treated with cyclosporine ophthalmic emulsion. Cornea 19:492–496 79. Vivino FB, Al-Hashimi I, Khan Z, LeVeque FG, Salisbury PL,Tran-Johnson TK, Muscoplat CC,Trivedi M, Goldlust B, Gallagher SC (1999) Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjogren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. P92–01 Study Group. Arch Intern Med 159:174–181 80. Yazdani C, McLaughlin T, Smeeding JE,Walt J (2001) Prevalence of treated dry eye disease in a managed care population. Clin Ther 23:1672–1682 81. Yerxa BR, Mundasad M, Sylvester RN, Garden JC, Cooper M, Kellerman DJ (2002) Ocular safety of INS365 ophthalmic solution, a P2Y2 agonist, in patients with mild to moderate dry eye disease. Adv Exp Med Biol 506:1251–1257 Fachnachricht Moderne Glaukompräparate werden günstiger Die am 1. Januar 2004 in Kraft getretene Reform des Gesundheitssystems macht moderne Glaukommedikamente billiger Glaukom-Patienten sind lebenslang auf ihre Augentropfen angewiesen, wenn sie die Krankheit unter Kontrolle halten wollen. Das Spektrum der Glaukommedikamente reicht von Miotika und Betablockern, die schon seit vielen Jahrzehnten in Gebrauch sind, bis zu den modernsten Prostaglandin-Analoga, wie z. B. dem Wirkstoff Latanoprost. Wegen ihres niedrigeren Preises werden die alten Glaukompräparate in Deutschland aber immer noch relativ häufig verschrieben. Die neue Arzneimittelpreisverordnung könnte hier zu einer Veränderung der Verschreibungspraxis beitragen. Gemäß der neuen Regelung werden die alten Glaukompräparate nämlich verteuert, die innovativen hingegen vergleichsweise erheblich günstiger. Den Augenärzten bietet sich also die Gelegenheit, bei ihren Glaukompatienten zukünftig vermehrt die modernen Wirkstoffe einzusetzen, ohne dabei ihr Budget zu sehr zu strapazieren. Die Zuzahlung des Patienten in der Apotheke ist im Übrigen ähnlich hoch, egal ob er ein altes, weniger wirksames Präparat mit vielen möglichen Nebenwirkungen erhält oder ein modernes, hoch wirksames und besser verträgliches Glaukom-Medikament. Quelle: Deutsches Grünes Kreuz e. V.
Seite 1 und 2: Ophthalmologe 2004 · 101:10-18 DOI
Seite 3 und 4: Zusammenfassung · Abstract Ophthal
Seite 5 und 6: 14 Tabelle 1 Tabelle 2 | Der Ophtha
Seite 7: 16 Cyclosporin A Lokal applizierbar

Das trockene Auge: Ein Update über Epidemiologie, Diagnose

Sie wollen auch ein ePaper? Erhöhen Sie die Reichweite Ihrer Titel.

Template löschen?

Als Template speichern?